CorMedix Inc. (CRMD)
- Previous Close
12.03 - Open
12.11 - Bid 11.59 x 300
- Ask 11.73 x 200
- Day's Range
11.42 - 12.31 - 52 Week Range
3.61 - 13.85 - Volume
4,566,241 - Avg. Volume
1,790,990 - Market Cap (intraday)
790.836M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
46.64 - EPS (TTM)
0.25 - Earnings Date Apr 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.83
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
www.cormedix.comRecent News: CRMD
View More
Performance Overview: CRMD
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRMD
View MoreValuation Measures
Market Cap
790.84M
Enterprise Value
713.81M
Trailing P/E
46.64
Forward P/E
17.95
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.72
Price/Book (mrq)
6.88
Enterprise Value/Revenue
8.65
Enterprise Value/EBITDA
40.40
Financial Highlights
Profitability and Income Statement
Profit Margin
20.81%
Return on Assets (ttm)
8.31%
Return on Equity (ttm)
19.87%
Revenue (ttm)
82.55M
Net Income Avi to Common (ttm)
17.18M
Diluted EPS (ttm)
0.25
Balance Sheet and Cash Flow
Total Cash (mrq)
77.5M
Total Debt/Equity (mrq)
0.41%
Levered Free Cash Flow (ttm)
-21.07M